IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer
Trial showed statistically-significant and clinically meaningful benefit in patients with the most aggressive type of lung cancer WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca…